Proqr Therapeutics Eo 04 Stock Gross Profit
| 0PQ Stock | EUR 3.40 0.01 0.29% |
PROQR THERAPEUTICS EO 04 fundamentals help investors to digest information that contributes to PROQR THERAPEUTICS's financial success or failures. It also enables traders to predict the movement of PROQR Stock. The fundamental analysis module provides a way to measure PROQR THERAPEUTICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PROQR THERAPEUTICS stock.
PROQR |
PROQR THERAPEUTICS EO 04 Company Gross Profit Analysis
PROQR THERAPEUTICS's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current PROQR THERAPEUTICS Gross Profit | 2.4 M |
Most of PROQR THERAPEUTICS's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PROQR THERAPEUTICS EO 04 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, PROQR THERAPEUTICS EO 04 reported 2.4 M of gross profit. This is 99.89% lower than that of the Healthcare sector and 99.75% lower than that of the Biotechnology industry. The gross profit for all Germany stocks is 99.99% higher than that of the company.
PROQR Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PROQR THERAPEUTICS's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PROQR THERAPEUTICS could also be used in its relative valuation, which is a method of valuing PROQR THERAPEUTICS by comparing valuation metrics of similar companies.PROQR THERAPEUTICS is currently under evaluation in gross profit category among its peers.
PROQR Fundamentals
| Return On Equity | -0.75 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (16.95) % | |||
| Shares Outstanding | 71.43 M | |||
| Shares Owned By Insiders | 20.89 % | |||
| Shares Owned By Institutions | 41.47 % | |||
| Revenue | 3.93 M | |||
| Gross Profit | 2.4 M | |||
| EBITDA | (66 M) | |||
| Net Income | (46.56 M) | |||
| Cash And Equivalents | 75.84 M | |||
| Cash Per Share | 1.51 X | |||
| Total Debt | 34.28 M | |||
| Debt To Equity | 0.61 % | |||
| Current Ratio | 7.77 X | |||
| Book Value Per Share | 0.91 X | |||
| Cash Flow From Operations | (47.06 M) | |||
| Earnings Per Share | (0.92) X | |||
| Target Price | 24.96 | |||
| Number Of Employees | 181 | |||
| Beta | 0.22 | |||
| Market Capitalization | 207.46 M | |||
| Z Score | 3.6 |
About PROQR THERAPEUTICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PROQR THERAPEUTICS EO 04's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PROQR THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PROQR THERAPEUTICS EO 04 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in PROQR Stock
PROQR THERAPEUTICS financial ratios help investors to determine whether PROQR Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PROQR with respect to the benefits of owning PROQR THERAPEUTICS security.